Pere Domingo
Pere Domingo is an expert in Infectiology at Hospital de Sant Pau (Spain). As of October 2026, ScienceLeadR ranks Pere Domingo in the top 1% of experts worldwide for HIV Infections, and in the top 1% of experts in Spain for Meningitis. Pere Domingo has authored 857 publications, the most recent in 2026, and is an investigator in 50 clinical trials, 4 of them ongoing. SLR score: 2,153 (community average: 125). How the SLR is computed.
LeadR Profile
Infectiology
Subspecialties: Public Health - Immunology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1981 - 2026
Number : 857
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Elucidating the mechanism underlying incomplete immune recovery in people living with HIV through CD4⁺ and CD8⁺ T cell multi-omics. PMID 42875740 — cells, stress, physiological, multiple chronic conditions, recycling, oxidative stress, therapeutics, t-lymphocytes | Mol Med | 2026 | 0 |
| Adherence to European AIDS clinical society hepatitis B management guidelines in people with HIV: real-world evidence from Spain and Germany. PMID 42847908 — cd4 lymphocyte count, cells, research design, guideline adherence, cross-sectional studies, liver, acquired immunodeficiency syndrome, enzymes, viruses, therapeutics, hepatitis b, infections, hepatitis | AIDS | 2026 | 0 |
| Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL). PMID 42841932 — cd4 lymphocyte count, hiv-1, safety, pharmaceutical preparations, drug therapy, drug-related side effects and adverse reactions, therapeutics | J Antimicrob Chemother | 2026 | 0 |
| Beyond Lipid Lowering: A Narrative Review and Expert Perspective on Precision Cardiovascular Prevention in People with HIV After REPRIEVE. PMID 42793086 — aging, cardiovascular diseases, biomarkers, hiv, precision medicine, atherosclerosis, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors | Biomolecules | 2026 | 0 |
| Community-acquired Pneumonia: Diagnostic Challenges in Non-immunocompromised Patients. PMID 42676152 — tomography, ultrasonography, biomarkers, pneumonia, immunocompromised host, radiography, thoracic, radionuclide imaging, community-acquired pneumonia | J Thorac Imaging | 2026 | 0 |
Clinical Studies 50
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 48
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Na ve Persons with HIV 1 (INNOVATE Study) 2025-521918-26-00 — hiv-1, tenofovir, safety, hiv, emtricitabine, therapeutics, hiv infections, infections | Phase 2 | Active not recruiting | 2026 |
| Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH A pilot proof of concept study (DORALI Study) 2023-504952-87-00 — pilots, fibrosis, liver, proof of concept study, hiv, viruses | Phase 4 | Active not recruiting | 2025 |
| An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor based antiretroviral therapy regimen in adults living with HIV (ENTRANCE) 2025-520629-19-00 — broadly neutralizing antibodies, antibodies, neutralizing, hiv, integrase inhibitors, therapeutics, integrases | Phase 1 | Active not recruiting | 2025 |
| PH2a VH4524184 Proof of Concept in Treatment Na ve Adults Living with HIV 1 2023-507173-18-00 — hiv-1, safety, hiv, therapeutics, hiv infections, antiviral agents, infections, pharmacokinetics | Phase 2 | Active not recruiting | 2024 |
LeadR Networks
Main global connection map